|
ZE Slides Up
|
6
|
Zenith Epigenetics
|
Jan 08, 2019 03:58PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:38PM
|
|
Re: NASH is a $35 Billion US/year market
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 07:21PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex / Pitavastatin
|
2
|
Resverlogix Corp.
|
Dec 04, 2018 09:19PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex / Pitavastatin
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 08:37PM
|
|
Re: Tundup
|
1
|
Resverlogix Corp.
|
Nov 30, 2018 10:53AM
|
|
Tundup
|
1
|
Resverlogix Corp.
|
Nov 30, 2018 10:13AM
|
|
Mace Events Study / Type 2 Diabetes / Control Arms 26 CVOT Trials
|
2
|
Resverlogix Corp.
|
Nov 28, 2018 12:50PM
|
|
Re: What is Mr. Market saying about RVX?
|
|
Resverlogix Corp.
|
Nov 25, 2018 11:27PM
|
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
6
|
Zenith Epigenetics
|
Nov 22, 2018 01:42PM
|
|
Re: J&J Abiraterone going generic
|
2
|
Zenith Epigenetics
|
Nov 21, 2018 03:48PM
|
|
J&J Abiraterone going generic
|
4
|
Zenith Epigenetics
|
Nov 21, 2018 02:31PM
|
|
Re: Inverted Hammer
|
1
|
Resverlogix Corp.
|
Nov 15, 2018 12:19PM
|
|
Re: Amarin CEO interview - New class action lawsuit
|
5
|
Resverlogix Corp.
|
Nov 14, 2018 08:13PM
|
|
Re: Amarin CEO interview
|
4
|
Resverlogix Corp.
|
Nov 12, 2018 02:35PM
|
|
Re: AHA 2018
|
3
|
Resverlogix Corp.
|
Nov 12, 2018 11:49AM
|
|
Re: AHA 2018
|
4
|
Resverlogix Corp.
|
Nov 12, 2018 09:22AM
|
|
Re: AHA 2018
|
4
|
Resverlogix Corp.
|
Nov 11, 2018 11:46PM
|
|
Re: Complement and AD
|
3
|
Resverlogix Corp.
|
Nov 11, 2018 03:09PM
|
|
Re: AHA 2018
|
5
|
Resverlogix Corp.
|
Nov 11, 2018 10:41AM
|
